Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

HIV Prevention for PLHIV: Evaluation of an Intervention Toolkit for HIV Care & Treatment Settings

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2012 by Centers for Disease Control and Prevention.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Columbia University
Namibia Ministry of Health and Social Services
Kenya Ministry of Health
Ministry of Health, Tanzania
Zanzibar Ministry of Health
Information provided by:
Centers for Disease Control and Prevention
ClinicalTrials.gov Identifier:
NCT01256463
First received: December 7, 2010
Last updated: April 4, 2012
Last verified: April 2012

December 7, 2010
April 4, 2012
October 2009
December 2011   (final data collection date for primary outcome measure)
  • Unprotected vaginal and anal sex [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Unprotected vaginal and anal sex [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Unprotected vaginal and anal sex [ Time Frame: 12-month follow-up ] [ Designated as safety issue: No ]
Unprotected vaginal and anal sex [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01256463 on ClinicalTrials.gov Archive Site
  • Number of sex partners [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Number of sex partners [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Number of sex partners [ Time Frame: 12 month follow-up ] [ Designated as safety issue: No ]
  • Number of sex partners getting an HIV test [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Number of sex partners getting an HIV test [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Number of sex partners getting an HIV test [ Time Frame: 12 month follow-up ] [ Designated as safety issue: No ]
  • Disclosure of HIV status to sex partners [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Disclosure of HIV status to sex partners [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Disclosure of HIV status to sex partners [ Time Frame: 12-month follow-up ] [ Designated as safety issue: No ]
  • Alcohol use [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Alcohol use [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Alcohol use [ Time Frame: 12-month follow-up ] [ Designated as safety issue: No ]
  • Adherence to HIV antiretroviral medications [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Adherence to HIV antiretroviral medications [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Adherence to HIV antiretroviral medications [ Time Frame: 12-month follow-up ] [ Designated as safety issue: No ]
  • Unintended pregnancy or partner pregnancy [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Unintended pregnancy or partner pregnancy [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Unintended pregnancy or partner pregnancy [ Time Frame: 12-month follow-up ] [ Designated as safety issue: No ]
  • Provision of family planning counseling and services [ Time Frame: Baseline ] [ Designated as safety issue: No ]
  • Provision of family planning counseling and services [ Time Frame: 6 month follow-up ] [ Designated as safety issue: No ]
  • Provision of family planning counseling and services [ Time Frame: 12-month follow-up ] [ Designated as safety issue: No ]
  • Number of sex partners [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
  • Number of sex partners getting an HIV test [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
  • Disclosure of HIV status to sex partners [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
  • Alcohol use [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
  • Adherence to HIV antiretroviral medications [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
  • Unintended pregnancy or partner pregnancy [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
  • Provision of family planning counseling and services [ Time Frame: Baseline, 6 month follow-up, 12-month follow-up ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
HIV Prevention for PLHIV: Evaluation of an Intervention Toolkit for HIV Care & Treatment Settings
HIV Prevention for People Living With HIV/AIDS: Evaluation of an Intervention Toolkit for HIV Care and Treatment Settings

The rapid scale-up of HIV care and treatment in resource-limited settings provides the opportunity to reach many HIV-positive individuals with prevention messages and interventions in care and treatment settings. However, HIV prevention is rarely incorporated into the routine care and treatment of people living with HIV, leaving missed opportunities to reach patients with critical interventions.

This study will evaluate an HIV prevention intervention package for health care settings in sub-Saharan Africa. The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (HCPs) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction. They will also assess and treat sexually transmitted infections (STIs) and provide basic contraceptives and safer pregnancy counseling.

Trained lay counselors (LCs) will deliver HIV prevention interventions in the clinics. LCs will be persons without medical training, many of whom will be PLHIV, who will be trained to provide HIV prevention counseling, promote HIV testing of partners and children (and provide HIV testing where allowed by national guidelines), and counsel HIV-positive patients on medication adherence and alcohol use.

The prevention intervention package will be evaluated in HIV clinics in three sub-Saharan African countries: Kenya, Namibia, and Tanzania. This project will be a longitudinal group-randomized trial with 9 intervention clinics (3 per country) and 9 comparison clinics (3 per country). Two hundred patients per clinic (total N = 3600) will be followed for 12 months. This evaluation will examine the effectiveness of the HIV prevention interventions delivered by HCPs and LCs on patient-level outcomes such as risky sexual behavior, disclosure of HIV status, partner HIV testing, alcohol use, HIV antiretroviral (ARV) medication adherence, STI treatment, pregnancies, and contraceptive use.

In addition to the patient outcomes, the acceptability of the interventions and materials, as well as the feasibility of integrating the interventions into HIV care and treatment settings, will be assessed.

Data will be collected via patient interviews, HCP and LC questionnaires, observations of HCP and LC patient visits, patient medical chart review, and review of clinic service data.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
HIV
Behavioral: HIV prevention intervention
  • No Intervention: Comparison
  • Experimental: HIV prevention intervention
    The HIV prevention intervention will be delivered to HIV-seropositive patients in HIV care and treatment clinics during all routine visits. Health care providers (including physicians, clinical officers, and nurses) will deliver HIV prevention messages on correct and consistent condom use, disclosure of serostatus, partner HIV testing, adherence and alcohol reduction during clinic visits. Health care providers will also assess and treat sexually transmitted infections (STIs), and provide basic contraceptives and brief safer pregnancy counseling.
    Intervention: Behavioral: HIV prevention intervention
Kidder DP, Bachanas P, Medley A, Pals S, Nuwagaba-Biribonwoha H, Ackers M, Howard A, Deluca N, Mbatia R, Sheriff M, Arthur G, Katuta F, Cherutich P, Somi G; PwP Evaluation Study team. HIV prevention in care and treatment settings: baseline risk behaviors among HIV patients in Kenya, Namibia, and Tanzania. PLoS One. 2013;8(2):e57215. doi: 10.1371/journal.pone.0057215. Epub 2013 Feb 25.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
3548
January 2013
December 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • At least 18 years old
  • HIV-positive patients receiving care at a project clinic and seen at the clinic at least twice prior to enrollment
  • Sexually active within the past three months
  • Planning to attend the clinic for at least 1 year
  • Able to conduct interview in one of the following languages:

Kenya: English, Kiswahili Namibia: English, Oshiwambo, Damara-nama, Otjiherero, Afrikaans Tanzania: English, Kiswahili

  • Able to provide informed consent to participate in the project

Exclusion Criteria:

  • Younger than 18 years of age
  • Not sexually active within the last three months
  • Planning to move from the vicinity of the clinic within one year
  • Not enrolled in the HIV clinic and/or have not been seen for at least two clinic visits
  • Cannot provide informed consent
  • Patients who are acutely ill or are determined by clinical staff to be too ill to participate
  • Spouses or identified partners of participating patients
  • Pregnant women and male partners of pregnant women, as family planning counseling and unintended pregnancy are some of the primary study outcomes
  • Not able to complete interview in one of the languages in the inclusion criteria
  • Participated in pilot study
Both
18 Years and older
Not Provided
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01256463
CDC-CGH-5540
No
Pamela Bachanas, US Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
  • Columbia University
  • Namibia Ministry of Health and Social Services
  • Kenya Ministry of Health
  • Ministry of Health, Tanzania
  • Zanzibar Ministry of Health
Principal Investigator: Pamela Bachanas, PhD Centers for Disease Control and Prevention
Study Director: Daniel Kidder, PhD Centers for Disease Control and Prevention
Centers for Disease Control and Prevention
April 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP